-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[China Pharmaceutical Network Enterprise News 】Recently, Rongchang biopharmaceutical (Yantai) Co., Ltd and Youhe Pharmaceutical Technology (Beijing) Co., Ltd signed a strategic cooperation agreement on antibody drug development in Yantai Rongchang biopharmaceutical park The two sides will jointly develop new drugs through technology transfer and technical cooperation, accelerate the industrialization process of innovative drugs, and work together for the early benefit of clinical patients Rongchang biology and Youhe medicine have been focusing on the development of innovative new biological drugs for a long time Under the guidance of the common development strategy, both sides have invested great efforts in the research and development of new antibody drugs for new targets Through the comprehensive evaluation of the early R & D pipeline of Youhe pharmaceutical and the production and development capacity of Rongchang biological new drug, the two sides fully affirmed their complementary relationship in the development of innovative biological drugs, and will jointly develop some new drugs Founded in 2008, Rongchang biology is committed to innovative biotechnology and the development of new biological drugs, and has made remarkable achievements It has been recognized as "national comprehensive new drug R & D technology platform (Shandong) industrial demonstration enterprise" and "national (enterprise) innovative drug incubation base" It has undertaken more than ten major scientific and technological special projects of "major new drug creation" and one "863" project At present, there are more than ten new drugs of antibody biology in the research and development pipeline, three of which are in the stage of clinical research and have made good progress The company has established the CHO cell expression system platform and antibody drug coupling (ADC) drug generic technology platform, and successfully developed the new ADC drug "rc48" which has entered the clinical research in China At present, Rongchang biology has 5 functional modules for mass production of antibody drugs and 4 core technologies for new drug creation of ADC, forming a new drug development, production and quality management system from gene cloning, cell bank establishment, small-scale expression, pilot scale-up to mass production The protein expression in the one-off bioreactor has reached the advanced level at home and abroad By actively attracting talents, improving the platform construction of innovative R & D, process and amplification, GMP production management, European and American drug quality management and new drug registration, the company has optimized key technologies such as cell line development, large-scale protein drug expression, purification, preparation, antibody small molecule poison coupling, etc., which can successfully carry out clinical application, clinical trial and business of new biological drugs at home and abroad Industrial production Youhe pharmaceutical is a high-tech enterprise located in Beijing Economic and Technological Development Zone, which is committed to innovative drug research and development Youhe pharmaceutical was founded in December 2016, and obtained 130 million yuan of round a investment from Baiao wealth and Guotou venture capital With the technical platform support of the company's strategic partners, we have successfully developed a variety of preclinical antibody products for new drug development At present, the antibody drug R & D pipeline of Youhe pharmaceutical is mainly concentrated in the field of tumor, and many products have entered the pre clinical research stage, and it is expected to start to apply for clinical trials in 2018 Youhe pharmaceutical seeks to cooperate with domestic and foreign pharmaceutical enterprises in the development of macromolecular drugs, including immunocheckpoint antibodies, bispecific antibodies, ADC, etc., to find a good treatment plan for cancer patients
For this cooperation, Lin Jian, chairman of Rongchang biology, introduced that the two sides are cooperating in the way of technology transfer Both sides have obvious advantages and can complement each other very well Youhe pharmaceutical is a well-known upstream R & D enterprise in China In terms of innovation ability, Rongchang biology, as the leader of the industry, has unique advantages in terms of production capacity Through Cooperation can achieve the goal of "1 + 1 > 2", and it is expected to realize the transformation of scientific research achievements within three years "We have a good foundation for cooperation before Through this cooperation, we will deepen ties We are not only optimistic about the current cooperation, but also have confidence in the future market prospects of biomedicine This cooperation mode of joint research and development of new biomedicine is a positive promotion for the whole pharmaceutical industry." Said Shen Yuelei, chairman of Youhe pharmaceutical Original title: strong "marriage" to promote the transformation of new and old kinetic energy Rongchang biology cooperates with you and medicine to jointly develop antibody drugs Seize the opportunity of pharmaceutical machinery and equipment industry, please download app (Pharma, Android version)!